This page shows the latest Revolade news and features for those working in and with pharma, biotech and healthcare.
The drug is in the same class as Novartis’ big earner Promacta/Revolade (eltrombopag) which is used to treat low platelet levels caused by hepatitis C virus infection, as well as ... The US biotech is continuing to target Revolade’s territory, and if
look at two other recent rejections – Novartis’ Revolade (eltrombopag) for severe aplastic anaemia and PTC Therapeutics’ Duchenne muscular dystrophy drug Translarna (ataluren).
Drug is in the same class as Novartis’ Promacta/Revolade. Dova Pharmaceuticals has won its first product approval, getting a green light from the FDA for Doptelet as a treatment for ... Doptelet is in the same class as Novartis’ Promacta/Revolade
Known as Revolade in most countries outside the US, Promacta gained its breakthrough therapy designation following positive data, which 52% of treatment-naïve severe aplastic anaemia (SAA) patients achieved complete response ... Regulatory filings for a
new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or
Revolade, Tafinlar and Mekinist all receive regulatory approval. Novartis has been granted EU approvals to three drugs acquired as part of its asset swap deal with GlaxoSmithKline, which closed earlier this ... year. The Swiss company announced this
More from news
Approximately 7 fully matching, plus 11 partially matching documents found.
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...